Reproductive system neoplasm

This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two par…

This early-stage trial is testing whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study will also look for signs that the drug m…

This early-phase study tested a combination of two oral drugs, abemaciclib and darolutamide, in 10 men with metastatic castration-resistant prostate cancer that had spread despite standard hormone therapy. The main goal was to check safety and side effects. The trial was terminat…

This phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (docetaxel and gemcitabine) helps people with advanced or recurrent uterine leiomyosarcoma. The study enrolled 107 participants but was terminated early. Researchers measured how long patients…

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …

This early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…

This study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested whether combining weight management (diet and exercise guidance) with a daily hormone pill (megestrol acetate) could help obese patients with early-stage endometrial cancer who want to preserve their fertility. The goal was to see if the cancer would completely …

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This phase 3 trial tested a combination of two targeted drugs, alpelisib and olaparib, against standard chemotherapy in 358 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum-based chemotherapy. The study only included women without a BRCA …

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study…

This early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…

This study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enroll…

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…

This early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…

This study tested a combination of two drugs—tivozanib and enzalutamide—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. Enzalutamide blocks male hormones that fuel cancer growth, while tivozanib cuts off the tumor's blood supply. The …

This phase II trial tested the drug niraparib (Zejula) in 11 men with high-risk prostate cancer that had not spread. All men had specific DNA repair gene mutations. They took niraparib before having their prostate removed surgically. The goal was to see if the drug could eliminat…

This study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the combo could lower PSA levels and ease pain. The trial was terminated early, so the findings a…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.

This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 p…

This phase 2 trial tested the drug cabozantinib in men with a hard-to-treat type of prostate cancer that had spread and stopped responding to hormone therapy. The study focused on patients whose tumors had specific genetic changes or had spread to the liver. Only 4 men were enrol…

This study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…

This early-phase study tested a personalized cell therapy made from a patient's own tumor-fighting immune cells. It aimed to see if the treatment was safe for people with advanced solid tumors that had spread or come back. Only 2 people took part before the study was stopped earl…

This study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …

This early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling …

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…

This early-phase study tested an experimental cell therapy called GT201, made from a patient's own immune cells, for advanced gynecological tumors. Only one person took part before the study was stopped early. The goal was to check safety and see if the treatment could shrink tum…

This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infus…

This study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the…

This early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminate…

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.

This early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…

This study looked at adding ribociclib to the standard hormone therapy enzalutamide for men with a certain type of advanced prostate cancer that had spread and no longer responded to hormone therapy alone. The goal was to find the best dose and see if the combination could lower …

This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

This trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…

This study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…

This phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…

This early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…

This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …

This early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…

This study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…

This study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) could help control recurrent ovarian cancer longer. It included people with a specific type of ovarian cancer that had come back but still responded to platinum chemot…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all …

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage study tested a new drug called TQB3720 in 192 men with advanced prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.

This study tested a combination of two drugs, futibatinib and pembrolizumab, in people with a specific type of advanced endometrial cancer that had spread and was not responding to standard treatments. The goal was to see if the combination could shrink tumors and provide lasting…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …

This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…

This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we ha…

This study tested a temporary biodegradable balloon placed between the prostate and rectum during radiation therapy for intermediate-risk prostate cancer. The goal was to see if the balloon could reduce radiation damage to the rectum by pushing it away from the prostate. The stud…

This study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …

This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…

This study tested whether giving a targeted radiation drug (LuPSMA) with or without an immunotherapy drug (ipilimumab) before prostate removal surgery is safe and feasible for men with very high-risk prostate cancer. Only one participant was enrolled before the study was stopped …

This early-phase study tested a new drug called GEN2, given with another drug (valganciclovir), in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated, so resul…

This study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped early, b…

This phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…

This early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…

This study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…

This study looked at whether a grape seed extract called OPC or the diabetes drug metformin could lower levels of AGEs (advanced glycation endproducts) in men with prostate cancer who are on hormone therapy. The trial planned to enroll 41 participants but was terminated early. Th…

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This phase 2 trial tested whether MRI-guided radiation therapy, given in fewer but higher doses, could safely treat high-risk prostate cancer while reducing side effects. The study enrolled 6 men with localized, high-risk prostate cancer who also received standard hormone therapy…

This study looked at whether a structured smoking cessation program starting four weeks before surgery could reduce complications in smokers undergoing intermediate to high-risk operations. Researchers planned to enroll 251 adult smokers scheduled for surgeries like abdominal, th…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…

This early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …

This study tested a new way to treat prostate cancer using a laser guided by MRI images. Only 2 men took part before the study was stopped. The goal was to see if the treatment was safe and could precisely target cancer while avoiding healthy tissue.

This phase 3 study tested a radioactive antibody called 177Lu-DOTA-rosopatamab combined with standard care for men with metastatic castration-resistant prostate cancer that had progressed after hormone therapy. The goal was to see if the combination slowed cancer growth or improv…

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …

This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …

This study tested a vaginal insert called ABI-2280 in women with cervical precancerous lesions (CIN). The goal was to see if it was safe and could help clear the abnormal cells. The trial was stopped early, so we don't have full results. It involved 44 women aged 25-55 who used t…

This early-phase study tested a new drug, WBC100, in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see how the drug moves through the body. The trial was terminated, so results…

This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This phase 2 study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The goal was to see if the drug could slow the cancer and to study bone and blood markers. The trial was terminated early, so results are limited.

This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…

This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…

This study tested a treatment for prostate cancer that came back after previous radiation. It combined temporary radioactive implants placed in the prostate, daily external radiation to the pelvis for 5 weeks, and 6 months of hormone therapy. The goal was to see if this approach …

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The s…

This study tested a drug called sacituzumab govitecan in people with ovarian, endometrial, or cervical cancer that returned after at least two rounds of standard treatment. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early with only …

This early-phase trial tested a new treatment called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. TC-E202 uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells…

This early-phase trial tested a personalized cancer treatment called tumor-infiltrating lymphocyte (TIL) therapy. Doctors took immune cells from each patient's own tumor, grew them in a lab, and infused them back to fight the cancer. The study enrolled only 5 adults with advanced…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …

This study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-bo…

This phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study w…

This study tested a new drug combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The combination included an immunotherapy drug (TQB2450) plus chemotherapy, with or without a targeted therapy (anlotinib). The goal was to …

This study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if Promitil could control tumor growth safely. The trial was terminated early,…

This study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated e…

This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopp…

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so resu…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…

This study aimed to see if taking letrozole (a hormone therapy) after standard treatment could help prevent endometrial cancer from coming back in patients with a non-specific molecular profile. The trial was stopped early after enrolling only 12 participants, so no firm conclusi…

This study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it…

This phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy…

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumor…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were to find a safe dose and check for side effects. The …

This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could sh…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This study aimed to see if the drug niraparib works better than standard chemotherapy before surgery for people with a specific type of advanced ovarian cancer (stage III or IV with HRd). The trial was planned for 36 participants but was stopped early. Researchers wanted to measu…

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

This early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be availa…

This early-phase study tested a new drug called BRY805 in 13 people with advanced solid tumors who had run out of standard treatment options. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited inform…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …

This early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full resu…

This study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…

This early-phase trial tested whether adding decitabine/cedazuridine to enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled before the study was terminated. The goal w…

This early-phase trial tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned (shown by rising PSA levels) after initial treatment like surgery or radiation. The therapy used two modified viruses to train the immune system to attack prost…

This study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …

This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…

This early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

This early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-stage trial tested an experimental drug called LY3127804, alone or combined with another cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find a safe dose. The study was terminated early, and researchers could not determine a max…

This early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This early-phase study tested a new drug called acapatamab in 212 men with advanced prostate cancer that had stopped responding to standard hormone therapy and chemotherapy. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety…

This early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…

This master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so result…

This phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…

This study looked at whether men with prostate cancer could take a lower dose of the drug abiraterone (combined with prednisone) and still control their cancer. About 50 men who had never taken abiraterone before were enrolled. The goal was to find the smallest dose that still lo…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women with a certain type of recurrent endometrial cancer. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many pati…

This study looked at whether a specific type of exercise, combining aerobic and resistance training in short bursts, could improve metabolic health in overweight or obese breast and prostate cancer survivors who had finished treatment. The goal was to reduce insulin resistance an…

This early-phase study tested the drug INCB086550 in 3 Japanese patients with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …

This study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the…

This early-phase trial tested a drug called RiMO-401, injected directly into tumors and followed by radiation, in people with advanced cancers that had not responded to standard treatments. Only 5 patients were enrolled before the study was terminated. The main goal was to find a…

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was termi…

This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results…

This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…

This early-phase trial tested a new immunotherapy drug called vudalimab (XmAb20717) alongside standard treatments for men with metastatic castration-sensitive prostate cancer. The study aimed to check safety and early signs of effectiveness. However, the trial was terminated earl…

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This study tested an oral drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to standard hormone therapy. The goal was to check safety and find the right dose, and to see if the drug could lower PSA levels. The trial was terminated early, so …

This early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …

This study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better th…

This study tested a new way to guide prostate biopsies by combining three imaging methods: a PET scan using a special tracer (fluorocholine), multiparametric MRI, and 3D ultrasound. The goal was to see if this triple approach could more accurately target suspicious areas in the p…

This study tested whether a special type of PET/CT scan, called PSMA PET/CT, can better detect if prostate cancer has spread to nearby lymph nodes before surgery. The scan uses a radioactive tracer that sticks to prostate cancer cells, making them visible. The goal was to help do…

This study looked at whether taking fewer systematic biopsy cores (6 instead of 20) during an MRI-targeted prostate biopsy could still detect dangerous prostate cancers while reducing risks like infection and overdiagnosis. The trial involved 126 men with suspicious MRI results. …

This study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…

This study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated…

This study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…

This study tested whether adding photoacoustic imaging to standard ultrasound can better tell if an ovary is cancerous or benign. Researchers aimed to reduce the number of women who have surgery to remove an ovary that turns out to be non-cancerous. The study enrolled 185 women s…

This phase 3 trial tested whether an iron-based contrast agent called Ferumoxtran-10 (Ferrotran®) could improve MRI scans to find prostate cancer that has spread to lymph nodes. The study involved 172 men with newly diagnosed prostate cancer at intermediate to high risk of spread…

This study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effe…

This study tested whether a combination of non-opioid medicines (ketamine, ketorolac, and acetaminophen) can control pain after robotic prostatectomy as well as standard opioid painkillers. Men aged 40-75 with prostate cancer were randomly assigned to receive either opioids or th…

This pilot study tested a mouthwash made with homoeriodictyol sodium to reduce bitter taste caused by chemotherapy in women with gynecologic cancers. The study aimed to see if the mouthwash could improve taste and food intake. Only 15 participants were enrolled, and the trial was…

This study looked at whether using a lower fluid pressure (60 mmHg) during hysteroscopy, a procedure to remove fibroids, works as well as the standard pressure (80 mmHg). The goal was to see if it improves surgery time, fluid use, and surgeon's view. The study was stopped early a…

This study looked at men with low or intermediate-risk prostate cancer to see if 2 MRI-guided radiation treatments cause fewer bowel and bladder side effects than 5 treatments. The goal was to find a shorter treatment plan that is just as safe and less bothersome. The study was s…

This trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants bu…

This Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…

This study tested whether placing a special placental tissue over nerves during prostate cancer surgery helps men regain erections and bladder control faster. Only 3 men participated before the study was stopped early. The approach aimed to protect nerves during surgery, but resu…

This study looked at whether a supplement called Q-Urol (made from quercetin, bromelain, rye flower pollen, and papain) could reduce prostate inflammation caused by radiation therapy in men with localized prostate cancer. Ten men who had brachytherapy (with or without other radia…

This study compared two devices used to collect tissue from the cervix during screening for cervical cancer: the standard Kevorkian curette and a softer cytobrush. The goal was to see if the cytobrush causes less pain while still getting enough cells for diagnosis. Only 3 women w…

This phase II trial tested whether Swedish massage can reduce fatigue in men who have had radiation for prostate cancer. The study enrolled 28 men aged 45 and older who reported significant fatigue. Researchers measured fatigue levels and inflammatory markers before and after mas…

This study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …

This pilot study looked at how the sleep drug zolpidem (Ambien) is processed in men with prostate cancer before and after they start hormone therapy that lowers testosterone. Researchers compared these results to healthy women, since women are known to have higher drug levels. Th…

This study looked at 14 men with intermediate-risk prostate cancer who were scheduled for prostate removal surgery. Each man received two different types of PET scans to see which one better highlights cancer cells. The goal was to compare the scans' ability to detect and measure…

This study aimed to compare how often women could go home the same day after a hysterectomy using three different minimally invasive techniques: vNOTES (through the vagina), conventional laparoscopy, and robot-assisted laparoscopy. The trial was terminated early after enrolling o…

This study aimed to see if a simple blood test could predict memory and thinking problems in men with prostate cancer receiving hormone therapy (ADT). Researchers planned to follow 32 men over time, comparing those on ADT to those not on it. The study was stopped early, so result…

This study looked at whether providing support for unmet basic needs—like food, housing, or transportation—helps low-income women attend their colposcopy appointment after an abnormal cervical cancer screening. The trial planned to enroll 72 participants but was stopped early wit…

This study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…

This study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal wa…

This pilot study tested whether a new PET imaging tracer called [18F]F-AraG could track immune T cells inside tumors of patients with advanced solid cancers who were receiving immunotherapy. Nine patients were enrolled to have PET scans and tumor biopsies before and after treatme…

This study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …

This study looked at whether MRI and PET scans taken two weeks into radiotherapy can predict if cervical cancer will be controlled. Researchers measured tumor size and activity in 9 patients with stage I to IIIB cervical cancer. The goal was to find early signs of treatment failu…

This study tested whether an online video simulator helps surgeons learn laparoscopic radical prostatectomy, a surgery for prostate cancer. It enrolled 29 surgeons who were new to the procedure, comparing those who used the simulator to those who did not. The trial was terminated…

This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…

This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, n…

This study looked at whether a special monitor (CardioQ-ODM+) could help doctors give the right amount of fluids during robot-assisted prostate surgery. The surgery uses gas and a head-down position, which can affect how well standard fluid monitors work. The study planned to inc…

This early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…

This study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…

This study looked at whether DNA markers found in urine can help detect prostate cancer. Researchers collected urine and prostate fluid samples from 24 men with or suspected of having prostate cancer. The goal was to see how accurate these markers are and to understand patient op…

This study tested whether combining two types of scans (PSMA-PET and MRI) can help doctors better target radiation for prostate cancer. The goal was to see if this approach is safe and possible. Only 8 people took part before the study was stopped early.

This study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…

This study aimed to find a better way to detect pelvic floor problems caused by radiation treatment for gynecologic cancer. Researchers tested a 5-minute single-digit pelvic exam on 22 patients undergoing chemoradiotherapy for cervical cancer. The goal was to see if this exam cou…

This study looked at how adults with advanced or metastatic solid tumors absorb, break down, and remove the drug subasumstat. Only 3 people took part, and the study was stopped early. The goal was to measure the drug in urine and stool, not to test if it works as a treatment.

This study offered genetic testing to men whose prostate cancer has spread to other parts of the body. Participants provided saliva samples to check for inherited mutations in about 30 cancer-risk genes. The goal was to understand how often these mutations occur and how men feel …

This early-phase study compared two radioactive drugs, lutetium rhPSMA-10.1 and Pluvicto, in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors and less to healthy organs like the kidneys. The study was te…

This study aimed to gather information from about 500 people with penile cancer to better understand the disease, its risk factors, treatments, and outcomes. Researchers did not provide any new treatment or intervention. The study was stopped early, but the data collected may hel…

This registry aimed to track pregnancy outcomes in women who were exposed to elagolix (brand names Orilissa and Oriahnn) for endometriosis or uterine fibroids. The study planned to enroll 584 pregnant women, half with elagolix exposure and half without, and follow them through pr…

This very early trial tested a single dose of HB-201 in 10 people with HPV 16+ throat or cervical cancer. The goal was to see how the drug affects the immune system, not to treat the cancer. The study was terminated early, so results are limited.

This study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metas…